Legend Biotech has managed to remove GenScript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuver ...
Legend Biotech (NASDAQ:LEGN) is one of the most promising mid-cap healthcare stocks under $50. As of December 19 closing, the ...
Analysts' ratings for Legend Biotech (NASDAQ:LEGN) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table encapsulates their recent ratings, offering a ...
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation created a window of reprieve for the affected biotech companies. The ...
Hosted on MSN
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024?
We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against the other ...
SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in ...
Legend Biotech (NASDAQ:LEGN) will release its quarterly earnings report on Wednesday, 2025-11-12. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Legend Biotech to ...
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial ...
Across the recent three months, 9 analysts have shared their insights on Legend Biotech (NASDAQ:LEGN), expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback